Differential effects of interleukin-2 blockade on apoptosis in naïve and activated human lymphocytes

Transplantation

Volumn 75, Issue 10, 2003, Pages 1631-1635

  Woodside, Kenneth J ^a   Hu, Mingdao ^a   Meng, Tao ^a   Hunter, Glenn C ^a   Sower, Laurie E ^a   Daller, John A ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; FAS ANTIGEN; INTERLEUKIN 2; PROTEIN BCL 2; THYMOCYTE ANTIBODY;

APOPTOSIS; CELL DEATH; CONFERENCE PAPER; DISEASE SIMULATION; DRUG EFFECT; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSPLANTATION TOLERANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTILYMPHOCYTE SERUM; APOPTOSIS; CALCINEURIN; CELLS, CULTURED; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; NECROSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RABBITS; RECOMBINANT FUSION PROTEINS;

EID: 0038350656     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000062973.32754.F7     Document Type: Conference Paper

References (24)

1. Baboolal K, Jones GA, Janezic A, et al. Molecular and structural consequences of early renal allograft injury. Kidney Int 2002; 61: 686-696.
2. Wolf G, Thaiss F, Stahl RA. Cyclosporine stimulates expression of transforming growth factor-β in renal cell. Possible mechanism of cyclosporine's antiproliferative effects. Transplantation 1995; 60: 237-241.
3. Weir MR, Ward MT, Blahut SA, et al. Long-term impact of discontinued or reduced calcineurin inhibitor in patients with chronic allograft nephropathy. Kidney Int 2001; 59: 1567-1573.
4. Mohamed MA, Robertson H, Booth TA, et al. TGF-β expression in renal transplant biopsies: A comparative study between cyclosporin-A and tacrolimus. Transplantation 2000; 69: 1002-1005.
5. Farges O, Nocci KA, Sebagh M, et al. Low incidence of chronic rejection in patients experiencing histological acute rejection without simultaneous impairment in liver function tests. Transplant Proc 1995; 27: 1142-1143.
6. Charlton M, Seaberg E. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: Results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Liver Transpl Surg 1999; 5: S107-S114.
7. Tippner C, Nashan B, Hoshino K, et al. Clinical and subclinical acute rejection early after liver transplantation: Contributing factors and relevance for the long-term course. Transplantation 2001; 72: 1122-1128.
8. Merion RM, Howell T, Bromberg JS. Partial T-cell activation and anergy induction by polyclonal antithymocyte globulin. Transplantation 1998; 65: 1481-1489.
9. Bonnefoy-Berard N, Verrier B, Vincent C, et al. Inhibition of CD25 (IL2Rα) expression and T-cell proliferation by polyclonal anti-thymocyte globulins. Immunology 1992; 77: 61-67.
10. Bonnefoy-Berard N, Genestier L, Flacher M, et al. Apoptosis induced by polyclonal antilymphocyte globulins in human B-cell lines. Blood 1994; 83: 1051-1059.
11. Daller JA, Hu M, Sower LE. Immunosuppressive regulation of naïve T-cell homeostasis. Surg Forum 2001; 52: 320-232.
12. Preville X, Flacher M, LeMauff B, et al. Mechanisms involved in antithymocyte globulin immunosuppressive activity in a nonhuman primate model. Transplantation 2001; 71: 460-468.
13. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194-1200.
14. Taniguchi Y, Frickhofen N, Raghavachar A, et al. Antilymphocyte immunoglobulins stimulate peripheral blood lymphocytes to proliferate and release lymphokines. Eur J Haematol 1990; 44: 244-251.
15. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172: 603-606.
16. Wells AD, Li XC, Walsh MC, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999; 5: 1303-1307.
17. Lenardo MJ. Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 1991; 353: 858-861.
18. Kneitz B, Herrmann T, Yonehara S, et al. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin2-deficient mice. Eur J Immunol 1995; 25: 2572-2577.
19. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5: 1298-1302.
20. Phillips KE, Herring B, Wilson LA, et al. IL-2Rα directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2/IL-2Rα interaction. Cancer Res 2000; 60; 6977-6984.
21. van Parijs L, Refaeli Y, Lord JD, et al. Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activationinduced cell death. Immunity 1999; 11: 281-288.
22. Deng G, Podack ER. Suppression of apoptosis in a cytotoxic T-cell line by interleukin 2-mediated gene transcription and deregulated expression of the protooncogene bcl-2. Proc Natl Acad Sci USA 1993; 90: 2189-2193.
23. Duke RC, Cohen JJ. IL-2 addiction: Withdrawal of growth factor activates a suicide program in dependent T cells. Lymphokine Res 1986; 5: 289-299.
24. Broome HE, Dargan CM, Krajewski S, et al. Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal. J Immunol 1995; 155: 2311-2317.